FINHUB Insights

BSX · Q1 FY25 · Jan 1 – Mar 31, 2025

Boston Scientific Q1 FY25: where the revenue came from and where it went

Boston Scientific Q1 FY25: revenue $4.7B (+21% year over year). Net profit $0.7B. Largest cohort Electrophysiology EP $0.7B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jan 1 – Mar 31, 2025
Reported
May 1, 2025 10-Q
Sankey diagram of Boston Scientific's income statement for Q1 FY25: revenue of $4.7 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$4.7B +21% year over year
Gross profit$3.2B 69% margin
Operating profit$0.9B 20% margin
Net profit$0.7B 14% margin

The numbers

All figures in billions of U.S. dollars, for Q1 FY25 (period ends Mar 31, 2025).
ItemValueShare of revenueYear over year
Revenue 4.7 100% +21%
Electrophysiology EP 0.7 15% +143%
Interventional Cardiology… 0.7 15% +7%
Global Endoscopy Endo Reporting… 0.7 15% +5%
Global Peripheral Interventions… 0.7 15% +14%
Global Urology and Pelvic Health… 0.6 13% +23%
Cardiac Rhythm Management 0.6 13% +1%
Watchman 0.4 9% +24%
Global Neuromodulation Nm… 0.3 6% +6%
Cost of revenue−1.532%
Gross profit3.269% margin+0pp
SG&A−1.634%−1pp
Other−0.715%+0pp
Operating profit0.920% margin+2pp
Tax−0.1
Interest & other costs−0.1
Net profit0.714%+2pp
Filing on EDGAR More quarters of BSX

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters